Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04516577
Other study ID # 2020073195
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2020
Est. completion date December 31, 2021

Study information

Verified date March 2022
Source Shanghai Pulmonary Hospital, Shanghai, China
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

By updating the chest HRCT scoring criteria of patients with pulmonary alveolar proteinosis, a new and more perfect system for evaluating the severity of alveolar proteinosis will be established.


Description:

In past, investigators summarized a method that was the severity and prognosis of pulmonary alveolar proteinosis (SPSP) to assess the severity and prognosis of patients with autoimmune pulmonary alveolar proteinosis (auto PAP). The SPSP included five aspects: smoking, symptom, PaO2, chest CT score at specific levels (aortic arch, carina, pulmonary vein confluence, and superior septal level) and DLCO %predicted. But the chest CT score only focused on range of lesions, and inaccurate. So, investigators plan to adopt new score which involves the assessing to range and density. In the new Chest HRCT score, we added the density score. The average density of the lesions at a particular level of the patient's chest HRCT was measured by computer and classified into three degrees: mild (less than -400), moderate (greater than -400 and less than -100) and severe (greater than 100), denoted as 1 ', 2 'and3', respectively. The range score of lung opacity was estimated using a five-point scale: no opacity = 0; opacity involving < 25% of a region of hemithorax = 1; 25-50% = 2; 50-75% = 3; and ≥ 75% = 4. The lesion score for each layer is equal to the density score multiplied by the range score. The chest HRCT score was calculated by summing the lung opacity scores of the four representative regions of each hemithorax, and divided into several level: no opacity = 0; ≤10 = 1; 11 - 20 = 2; 21 - 30 = 3; 31 -40 = 4; > 40 = 5. According to the new chest HRCT score, the SPSP will be updated to SPSP II. In this study, patients with auto PAP from three centers (Shanghai Lung Hospital, Peking Union Medical College Hospital and Nanjing Drum Tower Hospital) were enrolled to evaluate the severity of disease severity score (DSS), SPSP and SPSP II, respectively, to evaluate the pros and cons of different scores and their impact on prognosis. About 30 newly diagnosed auto PAP patients were recruited, and were assess disease severity on the basis on SPSP II scores. According to SPSP II scores, appropriate treatment was used for the patients, who were followed up for 3 months.


Recruitment information / eligibility

Status Completed
Enrollment 231
Est. completion date December 31, 2021
Est. primary completion date December 31, 2021
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - The patients had be diagnosed with autoimmune pulmonary alveolar proteinosis through pathology or bronchial alveolar lavage fluid (BALF). - The patients are old than 18 year. - .Every patient had a complete medical history, chest HRCT, pulmonary function and arterial blood gas analysis. - The patients have high level antibody of GM-CSF in serum or BALF. Exclusion Criteria: - The patients had a congenital or secondary pulmonary alveolar proteinosis.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Assesssing the severity of pulmonary alveolar proteinosis
Three severity scores will be used to assess the severity of patients with pulmonary alveolar proteinosis.

Locations

Country Name City State
China Shanghai pulmonary hospital Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Shanghai Pulmonary Hospital, Shanghai, China

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The severity and prognosis of pulmonary alveolar proteinosis The second severity and prognosis score of PAP (SPSP II) involves the range and density of lesion in chest CT of patients From July 2020 to December 2021
See also
  Status Clinical Trial Phase
Terminated NCT00030056 - GM-CSF in Patients With Pulmonary Alveolar Proteinosis Phase 2
Completed NCT03887169 - Administration of Methionine in Patients With Pulmonary Alveolar Proteinosis by Mutation of the MARS Gene. Phase 1/Phase 2
Completed NCT02468908 - Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects Phase 1
Enrolling by invitation NCT04326036 - Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection Early Phase 1
Completed NCT03007134 - Multicenter International Cross-Sectional Evaluation of Pulmonary Alveolar Proteinosis Trial N/A
Recruiting NCT01983657 - Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP. Phase 2
Completed NCT00552461 - Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis Phase 2
Recruiting NCT02852928 - European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank
Completed NCT02081092 - Evaluation and Treatment Planning of Patients With PAP Using Thrive Ultra Short Echo Time MRI and CT
Recruiting NCT03316651 - Sequential Therapy With WLL/Inhaling GM-CSF for Autoimmune Pulmonary Alveolar Proteinosis Phase 2
Enrolling by invitation NCT05300360 - Prevalence of Adenosine Deaminase (ADA) Enzyme Deficiency Disease in Adult Patients With Pulmonary Alveolar Proteinosis
Recruiting NCT02461615 - A National Registry For Pulmonary Alveolar Proteinosis